Preparation and LC/MS Analysis of Oligonucleotide Therapeutics from Biological Matrices

Mar 24 2011

Author: James Rudge, Greg Scott, Mark Hail, and Michael McGinley on behalf of Phenomenex Inc

Free to read

This article has been unlocked and is ready to read.


Due to their association with other biomolecules as well as their unique chemical properties, oligonucleotide therapeutics present unique challenges in their isolation and LC/MS analysis from biological matrices. A new isolation protocol using a mixed-mode SPE cartridge is presented that demonstrates high recovery and sensitivity into the low ng/mL range. Optimization of LC/MS mobile phase conditions as well as MS analysis parameters results in improved sensitivity and identification of oligonucleotides and their metabolites.

Therapeutic uses of oligonucleotides are becoming an increasingly popular approach to treat disease. Since the human genome was fully decoded back in 2003, researchers are gaining a rapid and comprehensive understanding of which genes code for which processes in normal human physiology. Gaining knowledge of what is normal has allowed scientists to identify abnormalities in genes which lead to disease states. Such abnormalities manifest in the incorrect coding of proteins which then leads to downstream problems with cell physiology.

Free to read

This article has been unlocked and is ready to read.


Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


EuCheMS Chemistry Congress

Jul 07 2024 Dublin, Ireland

HPLC 2024

Jul 20 2024 Denver, CO, USA

ICMGP 2024

Jul 21 2024 Cape Town, South Africa

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA

JASIS 2024

Sep 04 2024 Chiba, Tokyo, Japan

View all events